PILLSKILL / INFORMATION

Sources & editorial standards

Every medicine profile links to the source used for its safety summary. We summarize in original language and direct readers to the full information.

How the original 100 medicines were selected

The original edition follows the first 100 entries in the ClinCalc DrugStats 2024 prescription-use table, checked November 19, 2026. The table is based on U.S. prescription-utilization estimates; it is not a real-time count and does not rank danger. Combination products are separate entries. Some products also have nonprescription uses. Formulations are not interchangeable: where the dataset groups an ingredient, a profile identifies the particular route it covers.

How expansion batches are selected

The expansion adds distinct medicines and clinically meaningful formulations from NIH / MedlinePlus drug monographs. Brand-name duplicates are not used to inflate the count. It is broader coverage, not a ranking of the 1,000 most prescribed or most dangerous drugs. Each published summary receives a medicine-specific source check before import; collected research records do not count as published profiles. The first expansion batch contains 50 profiles, including an explicitly historical entry for obeticholic acid with its FDA withdrawal record. No independent clinician review has been performed.

Medical-source hierarchy

For medicine-specific information, this edition uses NIH / National Library of Medicine MedlinePlus drug monographs and FDA prescribing information and safety communications. MedlinePlus monographs include AHFS patient information; the original material remains copyrighted by its respective owner. We link to it rather than reproduce it.

Broader context comes from Mayo Clinic’s pain-medicine discussion, Mayo Clinic’s sleeping-pill overview, Cleveland Clinic’s antibiotic overview, and individual peer-reviewed studies indexed in PubMed. PubMed indexing does not itself establish a study’s quality or prove causation.

How to read a risk statement

Benefits and treatment risks

The SPRINT randomized trial’s final report illustrates why both belong in the discussion: intensive blood-pressure treatment reduced major cardiovascular events and deaths in its selected study population, while some serious adverse events were more frequent. Its findings are not an instruction to use one target for everyone.

Keeping warnings current

Initial source checks began November 19, 2026. Later expansion profiles show their individual source-check dates. FDA hormone-therapy labeling changed in 2026; testosterone labeling also changed following newer evidence. A statement in an older monograph may not describe the latest product-specific label. Profiles link to current FDA context where those changes matter. This site has no automatic safety-update feed; always consult the current label and a healthcare professional.

Editorial transparency

This edition is an AI-assisted editorial compilation and has not been independently reviewed by a licensed clinician. We do not claim hospital affiliation or medical certification. Corrections should be checked against the original source and current prescribing information before publication.